Effects on choroidal neovascularization after anti-VEGF upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 3, 2010, Pages 1671-1676

  Framme, Carsten ^a,b   Panagakis, Georgios ^a   Birngruber, Reginald ^c  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b University Eye Clinic Bern   (Switzerland)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ARTICLE; CLINICAL TRIAL; CORNEA THICKNESS; DISEASE CLASSIFICATION; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; PHOTORECEPTOR; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA EDEMA; RETINA MACULA AGE RELATED DEGENERATION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; DRUG ANTAGONISM; FLUORESCENCE ANGIOGRAPHY; INJECTION; OPTICAL COHERENCE TOMOGRAPHY; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77949899124     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4496     Document Type: Article

References (17)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900-1901.
2. Eye Disease Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
5. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-248.
6. Neue Aspekte in der Therapie der neovaskulären altersbedingten Makuladegeneration. Aktuelle Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands e. V. (Stand März 2009). Ophthalmologe. 2009;106:457-464.
7. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:3115-3120.
8. Golbaz I, Ahlers C, Schütze C, et al. Influence of antiangiogenetic therapy on retinal thickness values in age-related macular degeneration (in German). Ophthalmologe. Published online March 25, 2009.
9. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UEK. Effects of Ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol. 2009. 2009;147(5):831-837.
10. Sayanagi K, Sharma S, Yamamoto T, Kaiser P. Comparison of spectral-domain versus time-domain optical coherence in management of age-related macular degeneration with Ranibizumab. Ophthalmology. 2009;116(5):947-955.
11. Kiss CG, Geitzenauer W, Simader C, Gregori G, Schmidt-Erfurth U. Evaluation of ranibizumab-induced changes of high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci. 2009;50(5):2376-2383.
12. Framme C, Walter A, Prahs P, Regler R, Theisen-Kunde D, Brinkmann R. Structural changes of the retina after conventional laser photocoagulation and selective retina treatment (SRT) in spectral optical coherence tomography. Curr Eye Res 2009;34(7):568-579.
13. Bolz M, Ritter M, Polak K, et al. The role of stratus OCT in anti-VEGF therapy qualitative and quantitative assessment of neovascular AMD (in German). Ophthalmologe. 2008;105(7):650-655.
14. Kaiser PK, Blodi PA, Shapiro H, Acharya NR, MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:1868-1875.
15. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006;168:2036-2053.
16. Bressler NM. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group: photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin: two-year results of 2 randomized clinical trials. TAP report 2. Arch Ophthalmol. 2001;119:198-207.
17. Ahlswede W, Michels S, Birngruber R, Schmidt-Erfurth U. Threedimensional imaging of photodynamic effects and spontaneous course in choroidal neovascularization (in German). Ophthalmologe. 2004;101:675-681.